

Single Use and Shiny Stuff

Combine So You Can Produce Enough!

Rob Boulanger, PhD Process Specialist, CRB

Mihir Sanghvi Process Engineer, CRB

December 7, 2017

Amgen Process Development Scale-up Laboratory 360 Binney Street Cambridge, MA 02142

Single Use and Shiny Stuff

Agenda

- Introductions
 - Speakers
 - Quick Background on CRB
- Deconstructing the Buzzword
- What does "Closed" mean to your company?
- Good Stainless Steel Practices
 - CIP, SIP and maintaining the processing environment.
- Good Single Use Practices
 - Component inspection, bag deployment, tube manifold installation and tubing management.
- Single Use vs Stainless Steel
 - Media and Buffer Preparation
 - Teaching and Old Facility New Tricks
- Open Discussion



CRB

Overview

THE RELENTLESS PURSUIT OF SUCCESS. YOURS.™







Robert Boulanger, Ph.D., CRB Process Specialist



- 15 years experience
- Bulk of career manufacturing Vaccines
 - · Lead process development, technology transfer and manufacturing operations
 - Involved in FDA licensure of two production facilities
- BPOG Viral Segregation Task Group Contributing Team Member
- ASME Bioprocessing Equipment (BPE) SIP Task Group Contributing member
- Joined CRB in April 2015, Process Specialist, Compliance, Planner
 - · Based in the Rockville, MD Office

Mihir Sanghvi, CRB Process Engineer

- Joined CRB in Feb 2015
- Based in the Rockville, MD Office
- 10 years experience
 - Process Design
 - Start-Up & Commissioning
 - CIP/SIP Cycle Development and Optimization
 - Site Construction Support
- ASME Bioprocessing Equipment (BPE) SIP Task Group Contributing member





What does closed mean?

- Many different definitions of closed.
- Closed to/from what?
- Does closed mean clean and ready for processing?
- Why is closed processing important?
- What is the impact of closed processing on facility design?
- How do we demonstrate closed?
 - Accepted by your regulatory representatives
- Performing a closure analysis



Deconstructing the Buzzword

What does closed mean?



Defining Closed

- Closed system:
 - Designed and operated such that the <u>product is isolated and never</u> <u>exposed to the manufacturing environment.</u>
 - Transfers into or from these systems must be <u>validated as closed</u>.
 - Risk of contamination to the product or process <u>cannot be mitigated</u> by addition of HEPA filtration to the immediate environment housing that operation.
 - Environment is a No Impact System

Closed Process:

 Process stream that is never exposed to its environment from setup through process completion



Deconstructing the Buzzword

Defining Functionally Closed

- Functionally closed:
 - Closed systems that are opened between processing operations but are <u>"rendered closed" by a cleaning, sanitization or sterilization</u> <u>process</u> that is appropriate or consistent with the process requirements, whether sterile, aseptic or low bioburden.
 - Systems that remain closed during product exposure to the system but may be exposed to the environment between periods of product exposure.

Functionally closed processing:

 Process that is not exposed to the environment in presence product, but where system requires <u>open setup or intervention</u>



Example of Functionally Closed



Cell Culture in SS Bioreactor

Deconstructing the Buzzword

Defining "Open" Processes or Systems

- Open Process:
 - A process or system that is exposed to its environment before, during and/or after a process operation without appropriate measures to functionally close the process prior to use of the product stream.
 - Open operations performed in a BSC are still open operations.

Briefly Exposed Operations:

- Open processes containing process materials and/or product intermediates. These open processes are rendered closed by means of an appropriate closing process.
- Definition and Validation of the "pre-closure" incubation phase is critical.



Examples of Open and Briefly Exposed Operations



Deconstructing the Buzzword

"Protected" vs. "Briefly Exposed" vs. "Functionally Closed"



8

Deconstructing the Buzzword

Formal RA Program to Assess Ability to Close Process

- Select Subject Matter Experts (SMEs):
 - Quality, Manufacturing, R&D
- The Program. Define "Closed". Set the Risk Assessment Parameters
 - Develop Impact (Severity) & Likelihood Criteria
 - Pre-Establish Risk Matrix
 - Use Tools for systematic evaluations
 - Develop Closure Philosophy and Strategy
- Understand your process & systems, PFDs, Protocols, Batch Records
- Evaluate and Confirm "Closed"
- Assess & Develop Sound Risk Mitigation Plan Based on Science & Engineering NOT on Perception of Regulatory Requirements or Legacy



Deconstructing the Buzzword

Preparing for a Closure Analysis

- Develop Closure Strategy
- All open aseptic operations shall be performed in Grade A...
- Validate closing of all systems stated as closed
- \$ vs practicality vs risk vs...
- Develop a strategy to:
 - Close "closed" operations
 - House all operations appropriately
- Strategy must be approved by <u>all stakeholders</u>
- Initially applied to specific process then develop companywide philosophy



Our Journey begins with sound process understanding...

Closure Analysis: Develop and agree on the Definitions

Bioburden Control Specifications			
Control Level	Definition	Example	
	Bioburden is reduced to zero or sterile condition. Requires	Cell culture or fermentation processes and final product filling where	
3 - Aseptic/Sterile	absolute isolation from environment. Specification is	absence of microbial contamination is critical to performance of the	
	defined and typically < 1 CFU/100mL.	process or quality of final product.	
	Bioburden is reduced to acceptable levels. Process	Chromatography processes where a starile state is typically not	
2 - Low bioburden	solution is bacteriostatic or does not promote growth.	required but a 0.3 um filtration is in place as a measure of control	
	Sanitary though non-sterile conditions required.	required but a 0.2011 flitt ation is in place as a measure of control.	
1. Controlled bishunder	Richardon is controlled on on the limit minor biol encode	Media or buffer prep where raw material components are briefly	
1 - Controlled bloburden	bioburden is controlled so as to limit microbial growth.	exposed to the environment prior to sterile filtration.	

Closure Level	Definition
1 - closed/unexposed	Never been used such as γ -irradiated assemblies. Asepti connections include KleenPak, Lynx, GE, SaniTek and tubing welds
2 - cleaned & SIPd	Open connection that is CIPd and SIPd prior to use or previously autoclaved and connected aseptically
3 – cleaned & sanitized	System CIPd but not SIPd prior to use, remains isolated from environment during process
4 - briefly exposed	Process exposed to environment for brief period then rendered closed by filtration or sterilization.
5 - open	Connection open to environment without subsequent cleaning or sanitization prior to use. Examples include quick connects or TC connections that have not been or CIPd or SIPd



Deconstructing the Buzzword			Risk Ma	atrix	
Closure Analysis: Set up				Control Level	
the Closure Risk Matrix		_	1 Controlled bioburden	2 Low bioburden	3 Aseptic
		1 Closed / Unexposed	1	2	3
	le/	2 Cleaned / SIP'ed	2	4	6
	sure Lev	3 Cleaned / Sanitized	3	6	9
	ĊĶ	4 Briefly Exposed	4	8	12
		5 Open	5	10	15
	D:	ak Donking			
	10-15	Urgent	Immediate enginee Process must shu	ering and/or manage t down until repair is	emnt control.
	8-12	High Priority	Should be address management cont	ed with engineering	and/or ver medium and
	5-9	Moderate Priority	Should be address management cont	ed with engineering ol with preference of	and/or wer low priority
	3-4	Low Priority	Should be address management cont	ed with engineering ol without disruption	and/or to production but
	tical	Knowledge			ispe.org 18

9

Biopharmaceutical Manufacturing Facilities Baseline Guide





What is a Closed System?

A Closed System ≠ Sterile!!!

- Validated to show that there are sufficient layers of protection to mitigate the risk of contamination from the environment
- Environment housing the system is not a critical aspect of the process. Product is never exposed to outside environment.
- Risk of contamination of closed system cannot be mitigated by housing process in bioburden-free environment
- Contamination of a closed system represents a breach of that system.



BioPhorum Operations Group (BPOG)



BioPhorum Operations Group (BPOG)

- To create an environment where the global biopharmaceutical industry can collaborate and accelerate their rate of progress, for the benefit of all.
- Bringing leaders together to create future visions that focus the industry's energy on the key emerging opportunities;
- Mobilizing communities of the top experts around these opportunities, up and down the biopharma value chain;
- Creating partnerships that enable change and provide the quickest route to implementation and results;
- Replacing isolation with collaboration so that the industry shares, learns and builds the best solutions together;
- Making the journey better, faster, cheaper.



BioPhorum Operations Group (BPOG)

BioProcess International Conference & Exposition 26-29 October 2015



Is The "Belt And Suspenders" Approach Required?

- Many companies are implementing closed-system processing to achieve a high-level of contamination control – but within classified cleanrooms
- For concurrent multi-product manufacturing, many companies have implemented architectural segregation measures in addition to closedsystem processing measures

Connecting Pharmaceutical Knowledge ispecing 1

BioPhorum Operations Group (BPOG)



Is The "Belt And Suspenders" Approach Required?

- <u>Mission</u> Investigate and define how closed systems can be effectively applied to reduce the reliance on architectural, personnel, and procedural segregation for drug substance (DS) bio-manufacturing and greater use of Controlled Non-Classified (CNC) space while ensuring
- product quality and patient safety.
- Risk based assessments have allowed the industry to re-think traditional approaches to area classifications
- Focus on integrity of closed systems rather than reliance on secondary containment and environmental controls
- Newer technology and improved engineering & procedural controls, facility designs, bioprocess equipment and analytical test methods enables greater use of closed and functionally closed systems

💋 ISPE.

BPOG Workstream"

Closed Systems in CNC "Room classification

Connecting

Pharmaceutical

Mission

- Simplify & harmonise selection of room classification across the industry
- Consistent implementation by regulators and industry
- Common risk based approach
- Endorsement by internal and





- Improving product quality and patient access to products
- Simplified design
- · Reduction of capital and operational costs
- Reduced Cost of Quality

Knowledge

Knowledge

- Flexibility in facility operation
- Consistent regulatory feedback



ispe.org



ISPE.



Not so Quickly Cowboys!

SIP & CIP Principles



ASME BPE

Scope

- provides requirements for systems and components that:
 - are subject to **cleaning** and **sanitization** (incl **sterilization**)
 - cleaned in place (CIP'd)
 - steamed in place (SIP'd)
 - other processes used in the manufacturing of biopharmaceuticals.

provides requirements for

- single-use systems and components used in bioprocessing.
- This standard may be used, in whole or in part, for other systems and components where bioburden risk is a concern.



ASME BPE

Voluntary Consensus Standard

- Balanced group of experts:
 - Engineers, Consultants and Specialists
 - Component manufacturers
 - Drug manufacturers
- Updated every two years to meet industry accepted best practices
- Corrections & clarifications requested by anyone
- Single Use and Stainless Steel Equipment

Connecting

Pharmaceutical

Knowledge

 How to Close Bioprocess Systems





ispe.org | 30



ASME BPE Keys to Successful CIP - Action





ASME BPE Keys to Successful SIP – Saturated Steam



Air is your enemy! Water is your enemy! ASME BPE-2016 is your friend!



SD-2.3.1.1 Steam in Place. Equipment parts and components subjected to SIP should withstand continuous flow of saturated steam at a minimum temperature of 266°F (130°C) for duration of 100 hr minimum under continuous steady-state conditions. However, at the discretion of the owner/user, conditions that are more stringent may be imposed. The use of elastomers/fluoroelastomers (within a piece of equipment or certain process instrumentation) that may thermally degrade during SIP will need to be thoroughly evaluated by the owner/user or manufacturer. The overall life of the equipment may be shortened significantly if the correct elastomer or process instrument is not selected.



ASME BPE Keys to Successful SIP







Key to Success is Harmonization Baseline Challenging the Cleanroom ASME BPE-2016 Biopharmaceutical Paradigm for Biopharmaceutical Manufacturing of Manufacturing Facilities Bulk Drug Substances **Bioprocessing** Equipment Steven Chalk, Ryan Taber, Cost Prober, Paul GE, Tien Pallong, Malt Kennedy See Begalewicz, Jeff in of hopeoming and for length and othered ingl/west HOW TO CLOSE BY street states series unific of uni-states states at an adding unific states at a adding unific unific adding unific unific adding unific adding unific unific adding unific CIP AND SIP IMPACT OF CLOSED DEFINE "CLOSED" AGREE ON DEFINITION VALIDATE CLOSED OF CLOSED Tanari GAN Tgardon Tang ad Janie 2 Alber Tan Ada Tan Ada Tan Ada Tan Tan Tan Ada AGREE ON DEFINITION OF CLOSED RNATIONAL STANDARD BioPhorum SME 💋 ISPE. Pharmaceutic Knowledge

ASME BPE Defining System Boundary





ASME BPE Defining System Boundary







ASME BPE

Recall Keys to Successful CIP

TACT

- Temperature
- Action
- [Chemistry]
- Time

Therefore monitor:

- Temperature
- Flow, Pressure, Rotation, Inspect
- Conductivity, pH
- Time

Ensure appropriate hydraulics





ASME BPE

Appropriate Conditions for Successful CIP



5 ft/sec velocity in tubing

- No dead legs
- Hydraulic balance
- Pump capacity
- 3 gpm / ft of circumference

Efficient evacuation

- Tank bottom valve
- Ring seal vacuum pump
- Low points

Monitor flow & press

- Plugged spray devices
- Leaks





ASME BPE

Appropriate Conditions for Successful SIP

- Monitor temperature & pressure
 - All RTDs +/- 1°C
 - > 130°C requires special materials
 - >24 psig requires special materials
- Effective draining
 - Trap lines
 - Low point drains, no dead legs
- Overlap of steaming on separate SIPs
- No vacuum
- Maintain integrity/closure







Field Observations Disclaimer

 The following slides represent a compilation of field observations from various biotech facilities. These photographs were provided with permission to present to biopharmaceutical society conferences in an effort to help improve designs and installations. Every effort has been made to hide the identity of the sources of these images. If you recognize any settings, we ask that you not disclose the sources.





Field Observations SIP Monitoring Points



Field Observations Initial SIP Conditions





Field Observations SIP conditions lead to damage





Field Observations Installation affects SIP Performance



Field Observations Installation affects CIP and SIP Performance



Field Observations Ingold™ fittings: Different shapes and sizes



Field Observations Recommended and Accepted Sidewall Designs



Field Observations Design affects CIP and SIP Performance



Field Observations Post SIP Vacuum Condition

Death by vacuum









Stainless Steel Biomanufacturing







Single Use Technology Implementation

Single Use Technology Implementation Well Suited For

- Retrofits accommodating new products
- Process change adding new addition buffer/media
- Clinical manufacturing
- Applications where SIP or CIP capability is limited
- Small volume applications (2000L or less)
 - At beginning (small volume Cell Culture) and end (sterile bulk fill)
- New, uncharacterized processes
- Products requiring frequent changeovers
- Cost of Goods driven???
- Ultra fast-track projects with low capital budget
 - (BUT customization adds time & \$)

Connecting

- Key Features:
 - Vendor supplied pre-sterilized and as a 'closed' system

Pharmaceutical

Knowledge

• No CIP or SIP required





Single Use versus Stainless Steel

Single Use-based facility requires:

- Less Capital
 - No Integrated CIP & SIP
 - Reduced HVAC for Clean Space
 - Reduced Clean Space Footprint
- Potentially Less Expense
 - Minimal separation of personnel (ballroom & closed processing)
 - More flexible
 - Lean process Less idle equipment time
- Less construction time
 - Allows more time between clinical results and commercial launch



Single Use versus Stainless Steel Issues to Consider

- Single use systems are scale limited:
 - Bioreactors = 2,000L (ABEC just introduced 4,000L unit)
 - Tubing = ~1 inch (weldable, dry), <1" (weldable, wet), general use 1-1/2"
 - Solution Prep (mixing) = 5,000L (only one vendor (ThermoFisher)
 - Storage Bags = 5,000L (fixed) and 1,000L (movable)
 - Chromatography systems & columns (60 cm max)
 - Depth Filtration, Viral Filtration & Ultrafiltration (may need multiple units)
- Heat Transfer
- Weight of high density solution hold

Connecting

- Warehousing & Disposal
- Lead times due to customization
- Sole sourcing can be considered to increase scale, however, supply chain risk must be assessed

Pharmaceutical

Knowledge





Operator Training: Set up, Deployment and Operation of SUS

- Tubing
 - Organized management systems
 - Connectors fasten properly
 - Unobstructed tubing flow path
- Ergonomics
 - Bag set up
 - Observation during processing
 - Confirm bag deploy properly
- Probe set up
 - Training on proper installation
 - Properly supported and protected
- Hands-on experience
- Visit vendor site or "Sand box



Single Use Best Practices

Initial Learning Curve with SUS Failure Risk





Initial Learning Curve with SUS Failure Risk

- Failures derive from a variety of causes:
 - Packaging / Unpacking
 - Poor Shipping / Handling
 - Storage conditions
 - Improper Installation
 - Legitimate failures from manual construction:
 - Attachment of clamps / fittings
 - Weld seems
 Zip tied hose barb connections
 - Manufacturer's defect





Single Use Best Practices

Tube Set Design Considerations

- Standardize Tube sets
 - Reduce number of unique tube sets
 - I.D.,O.D., and Length
 - Aseptic and quick connect (briefly exposed)
- Risk based approach
 - Determine appropriate connector requirements
 - Don't use aseptic connectors unless required.
 - Are pre-sterilized components/bags required?
 - Identify proper room classification
- Walk through deployment and setup strategy
 - Ergonimics





Tube Set "PIDs"

- Approach like SS piping
- What flushes are required?
- Sampling?
- Bag Fill/Dispense
 - Bottom/top
 - Multiple additions
 - Liquid
 - Solids
 - Open
 - Closed
 - Briefly Exposed
 - Dispense
 - Samples
 - Multiple batches
 - Multiple process steps



Single Use Best Practices

Tubing Management

- Transfers over long distances can require work at elevation which pose safety concerns.
- Overhead tubing transfers should be avoided.
- Stainless steel transfer lines are easy to clean so hybrid considerations should be evaluated where practical.





BILL OF MATERIA

NOTES



Tubing Management

- SS Cable Tray
- Tubing Support
- Custom Tubing Management system
- Tubing Trench



Single Use Best Practices

Tubing Pass-through



Iris Valve

Connecting

Pharmaceutical



AdvantaPass



Knowledge



Capped ports with inserts around tubing



ispe.org | 64

Tubing Identification

- Intelligent Couplings can help to confirm proper connections are made to prevent mix-ups
- Color coding of tubing or zip ties are another option to prevent confusion







Single Use Best Practices

Tubing Identification

- Airlocks must be sized to accommodate movement of media / buffer bags
- Must account for
- Door Swings
- Wipe Down Space
- Turning radius of palette jacks / movers
- Material movement / traffic studies are a good idea





Skided Solutions (Custom, Automated and or Manual solutions)





Media & Buffer Preparation

Process Assumptions

- Scale comparable to small and medium size biotech GMP facility. •
- 2000L Biotech Facility •
- Mab Model with Titer around 1.5 3 g/l .



Media Preparation

Single Use Mixers

Based on the process model and media requirements following sizes were selected (SUMs with jacket, load cells and temperature transmitters)-

- 1. 2000L
- 2. 500L
- 3. 200L



Stainless Steel Vessel

Following vessel sizes are comparable to the single use equipment selected -

- 1. 2000L
- 2. 650L
- 3. 200L

Stainless Steel Vessels are assumed as skid with capability to perform rinses, CIP and SIP.

For Media vessel the skids will be CIP'ed at end of each run. SIP will be on as needed basis.



Media Preparation

3-D Model of Media Skid



Single Use Bag Consumption and Unit Cost

Media Bag Consumption per Batch

- 2000L SUM 1 bag
- 500L SUM 2 bags
- 200L SUM 4 bags

Bag Unit Cost

- 2000L Bag \$2,000
- 500L Bag \$1,200
- 200L Bag \$1,000



Media Preparation

WFI Cost and Estimation for CIP

WFI Cost = \$ 0.07 per liter.

This cost does not include maintenance cost, inflation and equipment depreciation. It is assumed that site has WFI producing capability.

CIP Cost Estimate per Vessel -

- 2000L Vessel CIP (2800L) \$200
- 500L Vessel CIP (1700L) \$120
- 200L Vessel CIP (1000L) \$70



Equipment Cost Comparison

Single Use Mixer	Stainless Steel Vessel
2000L SUM - \$160,000	2000L Vessel* - \$300,000
500L SUM - \$110,000	650L Vessel* - \$260,000
200L SUM - \$80,000	200L Vessel - \$150,000
Total Capital Cost - \$350,000	Equipment Cost - \$710,000
* SUM Cost Includes SUM+TCU+Instruments+Load Cell	* Vessel Cost Includes Tanks+Valves+ Platform
Negligible	Automation Cost – \$100,000
Annual Maintenance - \$10,000	Annual Maintenance - \$60,000
Installation + Eng \$70,000	Installation + Eng \$140,000
Validation - \$50,000	Validation - \$140,000
No CIP Skid	CIP Skid (Equip+Instal) - \$400,000
Total - \$480,000	Total - \$1,550,000



Media Preparation

Operation Cost Comparison

Single Use Mixer	Stainless Steel Vessel
2000L Bags - \$2,000	2000L Vessel CIP - \$200
500L Bags - \$2,400	500L Vessel CIP - \$240
200L Bags - \$4,000	200L Vessel CIP - \$280
Total Bag Cost per Batch - \$8,400	WFI Cost per Batch- \$720
24 Batch Annually - \$226,800	24 Batch Annually - \$17,280
48 Batch Annually - \$403,200	48 Batch Annually - \$34,560

5 Year Analysis at 24 Batch/yr



Media Preparation

5 Year Analysis at 48 Batch/yr



Additional Key Decision Points

If Stainless Steel Option than -

- Additional Pre-Treatment capacity
- Bigger WFI Generation and Storage
- Clean Steam Generator

All this can significantly add to the capital cost.



Buffer Preparation

SUMs and Bag Consumption per Batch

Single Use Mixer (Size)	Number of Bags per Batch @1.5 g/l Titer	Number of Bags per Batch at 3 g/l Titer
2000L	2	4
1000L	5	6
500L	2	2
200L	1	4

SUMs are non-jacketed with load cells and have temperature transmitters.



Stainless Steel Vessel

Following vessel sizes are comparable to the single use equipment selected -

- 1. 2000L
- 2. 650L
- 3. 200L

Stainless Steel Vessels are assumed as skid with capability to perform rinses, CIP and SIP. Buffer Prep vessels during everyday operations will be rinsed with WFI.CIP and SIP on as needed basis and accounted in Annual Maintenance.

WFI Rinse Cost Estimate per Vessel -

- 2000L Vessel Rinse (10 mins*175 l/m*0.07) \$125
- 500L Vessel Rinse (10 mins*110 l/m*0.07) \$80
- 200L Vessel Rinse (10 mins*60 l/m*0.07) \$50

Connecting



Buffer Preparation

Equipment Cost Comparison

Single Use Mixer	Stainless Steel Vessel
2000L SUM - \$125,000	2000L Vessel* - \$300,000
1000L SUM - \$90,000	650L Vessel* - \$260,000
500L SUM - \$75,000	200L Vessel - \$150,000
200L SUM - \$60,000	
Total Capital Cost - \$350,000	Equipment Cost - \$710,000
* SUM Cost Includes SUM+Instruments+Load Cell	* Vessel Cost Includes Tanks+Valves+ Platform
Negligible	Automation Cost – \$100,000
Annual Maintenance - \$10,000	Annual Maintenance - \$60,000
Installation + Eng \$70,000	Installation + Eng \$140,000
Validation - \$50,000	Validation - \$140,000
No CIP Skid	CIP Skid (Equip + Instal) - \$400,000
Total - \$480,000	Total - \$1,550,000

Pharmaceutical

Knowledge



Operation Cost Comparison

Single Use Mixer	Bag Cost per Batch	Stainless Steel Vessel	Cost Per Batch	
	@ 1.5 g/l			
2000L = 2*2000	\$4000	2000L Vessel= 7 Rinses*125	875	
1000L = 5*1600	\$8000	650L Vessel = 1 Rinse*80	80	
500L = 1*1200	\$1200	200L Vessel = 2 Rinses*50	100	
200L = 2*1000	\$2000			
Total Cost/Batch	\$15,200	Total Cost per Batch	\$1055	
@ 24 Batches/Year	\$364,800	@ 24 Batches/Year	\$25,320	
@ 48 Batches/Year	\$729,600	@ 48 Batches/Year	\$50,640	



Buffer Preparation

5 Year Analysis at 24 Batch/yr



5 Year Analysis at 48 Batch/yr



Buffer Preparation

Operation Cost

Single Use Mixer	Bag Cost per Batch	Stainless Steel Vessel	Cost Per Batch
	@ 3	3 g/l	
2000L = 4 * 2000	\$8000	2000L Vessel = 10 Rinses * 125	\$1250
1000L = 6 * 1600	\$9600	650L Vessel = 2 Rinse * 80	\$160
500L = 2 * 1200	\$2400	200L Vessel = 4 Rinses * 50	\$200
200L = 4 * 1000	\$4000		
Total Cost/Batch	\$24,000	Total Cost/Batch	\$1610
@ 24 Batches/Yr	\$576,000	@ 24 Batches/Yr	\$38,640
@ 48 Batches/Yr	\$1,152,000	@ 48 Batches/Yr	\$77,280



5 Year Analysis at 24 Batch/yr



Buffer Preparation

5 Year Analysis at 48 Batch/yr



Media and Buffer Preparation

Additional Considerations

	Single Use Mixer	Stainless Steel
1	Bag Storage - Additional load on warehouse storage. Supply chain management. Dependency of vendor.	If existing facility than bigger WFI storage tank needed. If new facility than it could mean bigger pre-treatment skid, WFI generation and storage vessel.
2	Bag Disposal Cost – incineration, landfill (environmental impact)	Increased Process Waste Treatment
3	No cleaning validation needed.	Cleaning Validation & Requalification
4	Low annual maintenance	High annual maintenance (gasket replacement, agitator maintenance, re- passivation, tank cleaning and finishing)
5	No CIP Skid	CIP skid needed
6	Low flowrates	Can be pressure transferred, no flowrate restrictions
		I Knowledge ispe.org 8

Buffer Preparation

Higher Titers

- With increasing titers its becoming difficult sizing buffer vessels.
- Leads to high investment costs.
- Substantial space requirements.
- Higher running costs and time consuming



IN-LINE DILUTION SKIDS are key to managing variability.

- One size can fit all.
- Helps eliminating large buffer hold vessels
- Improved buffer consumption efficiency
- Better process floor space utilization
- Increases flexibility and throughput
- ouahout Expi
- Optimize or eliminates CIP

Key points to considerAbility to concentrate (5x, 10x...)

Expiration Date Strategy



Media and Buffer Preparation

Conclusion

- Both Single Use Technology and Stainless Steel options have their own unique sets of challenges and advantages.
- Identifying site key requirements (multiple products, space, number of batches, cadence...), conditions (new facility vs renovation) will help narrow down choice.
- <u>HYBRID</u> option would help in extracting the best of both worlds. This gives you increased flexibility, can significantly reduce operational cost and also offset high capital cost.





"Protein Sciences lauds benefits of Pfizer refit in commercial scale-up" Background – Licensed at 500L scale and wanted to go larger!

In January 2013, the US Food and Drug Administration (FDA) approved Protein Sciences Corporation's trivalent influenza vaccine Flublok, made using the firm's Baculovirus Expression Vector System (BEVS) rather than the influenza virus itself or eggs, as in other flu vaccines.

Up-scaling to commercial production was therefore needed, VP of Manufacturing Operations Mireli Fino said at last month's Biological Production Forum in Dublin, Ireland, especially in light of the firm's \$147,000 contract with the Biomedical Advanced Research and Development Authority (BARDA) to produce up to 50 million doses of Flublok within six months of a potential flu pandemic.

Greenfield Option – too much time and too much money

"The first thing we looked at was a greenfield facility, but the primary concerns with constructing a new facility is time and money," she continued, adding construction and validation would have taken up to five years, rather than the onetwo years' timeline the company was looking for.

CMO Option – path forward until...

Connecting

"The focus was then on contract manufacturing," she said, saying a CMO is the most expedient way to launch a commercial product. "We looked at companies in the US primarily and we narrowed it down from 30 companies to just two," with contract negotiations beginning in July/August 2012.

Pfizer lease was available

"[The Pfizer site] was a licensed manufacturing facility since 2000, just recently decommissioned and it had been fully qualified... There were relative minor expenses expected for equipment and it was ready for capacity expansion ... and Pfizer offered very attractive lease terms," so the firm moved in in December 2012.

https://www.biopharma-reporter.com/Article/2014/06/13/Protein-Sciences-lauds-benefits-of-Pfizer-refit-in-commercial-scale-up Pharmaceutical

Knowledge



Technology transfer and scale-up of the Flublok® recombinant hemagglutinin (HA) influenza vaccine manufacturing process

Barry Buckland^{a, c, *}, Robert Boulanger^a, Mireli Fino^a, Indresh Srivastava^a, Kathy Holtz^a, Nikolai Khramtsov^a, Clifton McPherson^a, Jamal Meghrous^a, Paul Kubera^b, Manon M.J. Cox^a

^a Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450, USA ABEC Corporation, Bethlehem, PA, USA Department of Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, UK

Article history:	Multiple different hemagglutinin (HA) protein antigens have been reproducibly manufactured at the 650
Received 10 April 2014	scale by Protein Sciences Corporation (PSC) based on an insect cell culture with baculovirus infection
Received in revised form 1 July 2014	Significantly, these HA protein antigens were produced by the same Universal Manufacturing process a
Accepted 21 July 2014	described in the biological license application (BLA) for the first recombinant influenza vaccine approved
Available online xxx	by the FDA (Flublok®). The technology is uniquely designed so that a change in vaccine composition
Keywords:	can be reachly accommodated from one HA protein anogen to another one. Here we present a vaccing
Flublok®	candidate to combat the recently emerged H7N9 virus as an example starting with the genetic sequence
Insect cell	for the required HA, creation of the baculovirus and ending with purified protein antigen (or vaccine
Recombinant HA	component) at the 10L scale accomplished within 38 days under GMP conditions.
Influenza vaccine	The same process performance is being achieved at the 2L, 10L, 100L, 650L and 2500L scale. An
Scale-up	illustration is given of how the technology was transferred from the benchmark 650 L scale facility to
Pandemic	a retrofitted microbial facility at the 2500 L scale within 100 days which includes the time for facility
H7N9	engineering changes.
	The successful development, technology transfer and scale-up of the Flublok® process has major impli
	cations for being ready to make vaccine تعترfidly on a worldwide scale as a defense against pandemi
	influenza. The technology described does not have the same vulnerability to mutations in the egg adapted
	strain, and resulting loss in vaceine efficacy, faced by egg based manufacture.
	© 2014 Elsevier Ltd, All rights reserved

 Lease approval to facility conversion and process demonstration batch completed in <100 days!

Buckland B, et al. Vaccine (2014), Volume 32, Issue 42, 22 September 2014, Pages 5496-5502 (http://dx.doi.org/10.1016/j.vaccine.2014.07.074)



Teaching an Old Facility New Tricks

The Pfizer manufacturing facility was a traditional stainless steel design for a vaccine produced using a microbial system

So would a Baculovirus/insect cell system FIT?:

- Fermenters/bioreactors were designed for a microbial system
 - Ruston impellers
 - No sparge capability
 - Media was sterilized in situ
 - Short incubation times in each vessel
- SS media and buffer systems
 - SS buffer/media preparation tanks
 - SS buffer hold tanks
- Continuous centrifuge
 - Supernatant contains product solids discarded
- Available downstream equipment
 - Large scale chromatography, filtration housings and TTF equipment available.
- Large autoclaves are available
 - Single use assemblies can be sterilized in house

Connecting

Manual ported valves allow SU integration with stainless steel Buckland B, et al. Vaccine (2014), Volume 32, Issue 42, 22 September 2014, Pages 5496-5502 (http://dx.doi.org/10.1016/j.vaccine.2014.07.074)

Pharmaceutical

Knowledge



ispe.org | 96

The Upstream HA process:



Teaching an Old Facility New Tricks

The Upstream Retrofit

💋 ISPE.

- SF+ Inoculum and P4 Virus stock preparation
 - Ability to store frozen virus stock and cell stock
 - Disposable shake flasks
 - Addition BSC required for required aseptic

Connecting



Pharmaceutical

Knowledge

ispe.org | 98





The HA Recovery process:



Fig. 3. Harvest of the suspension culture insect cell pellet by disk stack centrifuge at the 2500L scale.

Buckland B, et al. Vaccine (2014), Volume 32. Issue 42, 22 September 2014, Pages 5496-5502 (http://dx.doi.org/10.1016/j.vaccine.2014.07.074)





Teaching an Old Facility New Tricks The Downstream HA process: Protein Production Harvest ¥ Extraction Clarification Capture Purification DNA Removal ¥ TFF **Final Filtration** Cox.pdf; Meghrous, et al. Vaccine (2009) Volume 28, Issue 2, 11 December 2009, Pages 309-316 💋 ISPE. ispe.org | 102 Connecting Pharmaceutical Knowledge

Questions?

Please use the microphone indicated so our recording includes audio of your question

103